Plus Therapeutics, Inc. (NASDAQ: PSTV) began Monday in the green. The Houston-based company, a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces notice of an additional advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the second-largest public cancer research funder globally. This $1.9-million payment is part of the Company’s previously awarded $17.6-million grant and is the second non-dilutive financing received from CPRIT following the $1.6 million receipt announced in July 2025.
"Continued payments from CPRIT are supportive to our radiotherapeutic development initiatives, with a further $1.9 million in funding expected over the next 12 months, providing a steady source of significant non-dilutive financing,” said CFO Andrew Sims.
“The support from CPRIT builds on our active National Institutes of Health and Department of Defense grants, reflecting strong commitment for our clinical programs from strategic institutions. We continue to actively pursue additional grant opportunities to strengthen our capital position.”
“The funding supports and accelerates the Company’s clinical development of REYOBIQ™”, according to this morning’s news release, “for the ReSPECT-LM dose optimization trial and further develops the Company’s CNSide LM diagnostic test as a key pivotal trial endpoint.”
PSTV shares began the week up two cents, or 4.6%, to 43 cents.
